Teva has become the first company to secure approval for, and to introduce ‘at risk’, a generic rival to Valeant’s Uceris (budesonide) 9mg extended-release tablets in the US. Citing Iqvia data for the 12 months ended May 2018, the Israeli firm said the branded treatment for ulcerative colitis had annual US sales of US$196 million.
US Food and Drug Administration (FDA) approval for Teva’s extended-release tablets under the Actavis name in early July came after...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?